OraSure Technologies (NASDAQ:OSUR) Rating Lowered to Hold at StockNews.com

OraSure Technologies (NASDAQ:OSUR) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Thursday.

OraSure Technologies Stock Performance

Shares of NASDAQ:OSUR opened at $3.74 on Thursday. The firm has a market cap of $278.97 million, a PE ratio of 24.93 and a beta of 0.05. The firm’s 50 day simple moving average is $3.81 and its 200-day simple moving average is $4.05. OraSure Technologies has a one year low of $3.52 and a one year high of $8.04.

Hedge Funds Weigh In On OraSure Technologies

A number of institutional investors have recently modified their holdings of the stock. Orion Portfolio Solutions LLC increased its position in shares of OraSure Technologies by 10.7% during the fourth quarter. Orion Portfolio Solutions LLC now owns 61,170 shares of the medical instruments supplier’s stock worth $221,000 after acquiring an additional 5,929 shares during the period. Principal Financial Group Inc. increased its holdings in OraSure Technologies by 10.7% during the fourth quarter. Principal Financial Group Inc. now owns 73,137 shares of the medical instruments supplier’s stock valued at $264,000 after buying an additional 7,077 shares during the period. Koss Olinger Consulting LLC increased its holdings in OraSure Technologies by 9.4% during the third quarter. Koss Olinger Consulting LLC now owns 83,977 shares of the medical instruments supplier’s stock valued at $359,000 after buying an additional 7,247 shares during the period. Raymond James Financial Inc. purchased a new position in OraSure Technologies during the fourth quarter valued at approximately $37,000. Finally, Atom Investors LP purchased a new position in OraSure Technologies during the third quarter valued at approximately $49,000. 93.50% of the stock is owned by hedge funds and other institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.